+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 60Years
All Genders
ID07846033

Evaluating Safety and Pharmacokinetics of Single Doses of VK3019 in Overweight and Obese Adults Without Other Health Conditions

Led by Viking Therapeutics, Inc. · Updated on 2026-09-29

56

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating VK3019, an amylin and calcitonin receptor agonist, in overweight and obese adults without other health conditions. This Phase 1 randomized, double-blind, placebo-controlled study aims to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of single doses of VK3019 in participants aged 18 to 60 years with a body mass index between 27 and 40 kgm2. About 56 participants will be divided into seven cohorts, each receiving a single subcutaneous dose of VK3019 or a matching placebo. Each cohort begins with two sentinel participants dosed on the same day, one receiving VK3019 and one placebo. If no safety concerns arise within 48 hours, the remaining participants in the cohort receive the same dose. Safety Review Committee meetings guide dose escalation decisions throughout the study. Participants will be monitored for safety and drug levels for 36 days following dosing. Assessments include physical exams, laboratory tests, and safety reviews to evaluate any adverse effects. The study evaluates the pharmacokinetic profile and tolerability of VK3019 while ensuring participant safety during the observation period.

CONDITIONS

Brief Title

A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities

Research Team

H

Hubert C Chen, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here